A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Adverse reactions
- Acronyms OSLER-2; PROFICIO
- Sponsors Amgen
- 29 Mar 2019 Results (n=556) evaluating safety and efficacy results of evolocumab in japanese patients of the OSLER studies published in the Circulation Journal
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 This trial has been completed in Netherlands, according to European Clinical Trials Database record.